| A Comparison of Three Intravitreal Modalities of Branch Retinal Vein Occlusion Macular Edema. |
|
Han Song, Hee Jun Song, Ji Ho Yang, Do Gyun Kim |
|
Department of Ophthalmology, Myongji Hospital, Goyang, Korea. Kimdk89@empas.com |
| 망막분지정맥폐쇄 황반부종에서 세 가지 유리체강 내 약물주입술의 단기 효과 비교 |
|
송 한⋅송희준⋅양지호⋅김도균 |
|
명지병원 안과 |
Correspondence:
Do Gyun Kim,
Email: Kimdk89@empas.com
|
|
Received: 17 May 2018 • Revised: 23 June 2018 • Accepted: 28 August 2018 |
| Abstract |
PURPOSE
Short-term results regarding the efficacy of intravitreal bevacizumab, dexamethasone implants, and triamcinolone-bevacizumab in macular edema (ME) secondary to branch retinal vein occlusion (BRVO) were compared. METHODS: This study included 30 eyes of with BRVO and ME. Patients received the following treatments: 1.25 mg of bevacizumab (group 1, n = 9), 0.7 mg of dexamethasone as an implant (group 2, n = 12), or a combination of 2 mg of triamcinolone acetonide and 1.25 mg of bevacizumab (group 3, n = 9). Measurements of visual acuity and central macular thickness (CMT) with optical coherence tomography were performed at baseline, and at 1 and 3 months injection. RESULTS: Compared to baseline, the CMT was significantly decreased in all groups by 326.32 ± 149.32, 311.50 ± 58.54, and 282 ± 28.21, respectively, at 1 month and 407 ± 160, 348 ± 108, and 289 ± 66, respectively, at 3 months, but there was no significant difference within each group. Compared to baseline, best-corrected visual acuity (BCVA) was significantly increased in all groups at 1 month and 3 months. Using post hoc analysis, there was no significant difference in the degrees of BCVA gain, but in degrees of CMT reduction, groups 2 and 3 were significantly higher than group 1 at 1 month and only group 3 was significantly higher than group 1 at 3 months (p < 0.017). CONCLUSIONS: The intravitreal injection of bevacizumab, a dexamethasone implant, or a combination of triamcinolone-bevacizumab could be effectively used in the treatment of ME due to BRVO. For ME, steroid treatment showed a greater reduction percentage, and in the case of the triamcinolone-bevacizumab combination, we could cover the short half-life of bevacizumab and the complications of steroid use. In severe cases of ME, an intravitreal dexamethasone implant or a combination of triamcinolone and bevacizumab can be considered as the first-line therapy. |
| Key Words:
Bevacizumab;Branch retinal vein occlusion;Dexamethasone implant;Triamcinolone |
|
PDF Links
Full text via DOI
Download Citation
